Skip to content

Research at St Andrews

A dose ranging trial to optimize the dose of Rifampin in the treatment of tuberculosis

Research output: Research - peer-reviewArticle


Open Access permissions



Martin J Boeree, Andreas H Diacon, Rodney Dawson, Kim Narunsky, Jeannine du Bois, Amour Venter, Patrick P J Phillips, Stephen H Gillespie, Timothy D Mc Hugh, Michael Hoelscher, Norbert Heinrich, Sunita Rehal, Dick van Soolingen, Jakko van Ingen, Cecile Magis-Escurra, David Burger, Georgette Plemper van Balen, Rob E Aarnoutse

School/Research organisations


Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on pharmacokinetic, toxicity and cost considerations. Available data in mice and humans showed that an increase in dose may shorten the duration of tuberculosis treatment. Objectives: To evaluate the safety and tolerability, the pharmacokinetics and the extended early bactericidal activity of increasing doses of rifampin. Methods: Patients with drug-susceptible tuberculosis were enrolled into a control group of 8 patients receiving the standard dose of 10 mg/kg rifampin, followed by consecutive experimental groups with 15 patients each receiving rifampin 20 mg/kg, 25 mg/kg, 30 mg/kg and 35 mg/kg, respectively, for 14 days. In all patients isoniazid, pyrazinamide and ethambutol were added in standard doses for the second 7 days of treatment. Safety, pharmacokinetics of rifampin, and fall in bacterial load were assessed. Measurements and Main Results: Grade 1 and 2 adverse events were equally distributed between the five dose groups; there were 5 grade 3 events of which 1 was a possibly related hepatotoxicity. Areas under the time-concentration curves and peak serum concentrations of rifampin showed a more than proportional increase with dose. The daily fall in bacterial load over 14 days was 0.176, 0.168, 0.167, 0.265, and 0.261 log10CFU/ml sputum in the 10, 20, 25, 30 and 35 mg/kg groups respectively. Conclusions: Two weeks of rifampin up to 35 mg/kg was safe and well tolerated. There was a non-linear increase in exposure to rifampin without an apparent ceiling effect and a greater estimated fall in bacterial load in the higher dosing groups. Clinical trial registration available at www.clinicaltrials.gove, ID NCT01392911.


Original languageEnglish
Pages (from-to)1058-1065
JournalAmerican Journal of Respiratory and Critical Care Medicine
Issue number9
Early online date5 Feb 2015
StatePublished - 1 May 2015

    Research areas

  • Tuberculosis, Clinical trial, Rifampicin, Global health

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses

    Svensson, R. J., Aarnoutse, R. E., Diacon, A. H., Dawson, R., Gillespie, S. H., Boeree, M. J. & Simonsson, U. S. H. 7 Aug 2017 In : Clinical Pharmacology & Therapeutics. 103, p. 674-683 10 p.

    Research output: Research - peer-reviewArticle

  2. Pseudomonas aeruginosa intensive care unit outbreak: winnowing of transmissions with molecular and genomic typing

    Parcell, B. J., Oravcova, K., Pinheiro, M., Holden, M. T. G., Phillips, G., Turton, J. F. & Gillespie, S. H. Mar 2018 In : Journal of Hospital Infection. 98, 3, p. 282-288 7 p.

    Research output: Research - peer-reviewArticle

  3. OMNIgene.SPUTUM suppresses contaminants whilst maintaining Mycobacterium tuberculosis viability and obviates cold-chain transport

    Azam, K., Cadir, N., Madeira, C., Gillespie, S. H. & Sabiiti, W. 16 Feb 2018 In : ERJ Open Research. 4, 8 p., 00074-2017

    Research output: Research - peer-reviewArticle

  4. Detecting phenotypically resistant Mycobacterium tuberculosis using wavelength modulated Raman spectroscopy

    Baron, V. O., Chen, M., Clark, S. O., Williams, A., Dholakia, K. & Gillespie, S. H. 2018 Antibiotic Resistance Protocols. Gillespie, S. (ed.). New York, NY: Humana Press/Springer, p. 41-50 10 p. (Methods in Molecular Biology; vol. 1736)

    Research output: ResearchChapter

Related by journal

  1. A Step toward an Optimized Rifampin Dose Completed

    Boeree, M. J., Diacon, A. H., Dawson, R., Narunsky, K., du Bois, J., Venter, A., Phillips, P. P. J., Gillespie, S. H., McHugh, T. D., Hoelscher, M., Heinrich, N., Rehal, S., van Soolingen, D., van Ingen, J., Magis-Escurra, C., Burger, D., Plemper van Balen, G. & Aarnoutse, R. E. 15 Aug 2015 In : American Journal of Respiratory and Critical Care Medicine. 192, 4, p. 525-6 2 p.

    Research output: Research - peer-reviewArticle

  2. Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function.

    Jackson, C. M., Medical Research Council National Survey of Health and Development (NSHD) Respiratory Study Team & SpiroMeta Consortium 1 Oct 2011 In : American Journal of Respiratory and Critical Care Medicine. 184, 7, p. 786-795 10 p.

    Research output: Research - peer-reviewArticle

  3. Supervised step-down of inhaled corticosteroids in the community - An observational study

    Clearie, K. L., Jackson, C. M., Fardon, T. C., Williamson, P. A., Vaidyanathan, S., Burns, P. & Lipworth, B. J. Apr 2011 In : American Journal of Respiratory and Critical Care Medicine. 105, 4, p. 558-565 8 p.

    Research output: Research - peer-reviewArticle

ID: 167131622